Anti‐factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old

What is already known about this subject • Major bleeds with low‐molecular‐weight heparin have been reported at curative and prophylactic dosages. • Enoxaparin clearance depends on body weight, and therefore weight‐adjusted dosing is recommended to minimize interindividual variability in drug exposu...

Full description

Saved in:
Bibliographic Details
Published in:British journal of clinical pharmacology 2007-10, Vol.64 (4), p.428-438
Main Authors: Berges, A., Laporte, S., Epinat, M., Zufferey, P., Alamartine, E., Tranchand, B., Decousus, H., Mismetti, P.
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Anticoagulants
Anticoagulants - pharmacokinetics
Anticoagulants - therapeutic use
Biological and medical sciences
Blood Coagulation Factor Inhibitors
Blood Coagulation Factor Inhibitors - metabolism
Body Weight
Body Weight - physiology
Drug Monitoring
elderly
Enoxaparin
Enoxaparin - pharmacokinetics
Enoxaparin - therapeutic use
Factor Xa
Factor Xa - metabolism
Female
Glomerular Filtration Rate
Glomerular Filtration Rate - drug effects
Humans
Life Sciences
low‐molecular‐weight heparin
Male
Medical sciences
NONMEM
Pharmaceutical sciences
Pharmacodynamics
pharmacokinetic
Pharmacology
Pharmacology. Drug treatments
Prospective Studies
Risk Factors
Thromboembolism
Thromboembolism - prevention & control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:What is already known about this subject • Major bleeds with low‐molecular‐weight heparin have been reported at curative and prophylactic dosages. • Enoxaparin clearance depends on body weight, and therefore weight‐adjusted dosing is recommended to minimize interindividual variability in drug exposure and the risk of haemorrhage in patients treated at curative doses. • Monitoring of this treatment is recommended in curative indications in patients at risk. • The need for monitoring of patients at risk receiving prophylactic doses of enoxaparin, in this case the elderly, remains unclear. What this study adds • Clearance of enoxaparin at prophylactic doses is predictably related to body weight and creatinine clearance in the elderly. • The simplified Modification of Diet in Renal Disease formula seems to be most discriminating and powerful in detecting any influence of glomerular filtration rate in the elderly. • The influence of these covariates does not seem to be sufficiently clinically relevant to support routine assessment in the elderly. Aims Major bleeding complications with low‐molecular‐weight heparin (LMWH) treatment have been reported both in clinical studies and during postmarketing surveillance. Monitoring of antifactor Xa (anti‐Xa) activities is therefore recommended in special populations often predisposed to renal impairment. The PROPHRE.75 study was conducted to estimate the distribution parameters of anti‐Xa activity in the elderly. Methods PROPHRE.75 was a prospective study of a cohort of consecutive patients aged >75 years and treated with 4000 IU of enoxaparin once daily for venous thromboembolism prophylaxis. Dosing history and measurements of anti‐Xa activity in sparse samples were recorded throughout treatment. The covariates included weight, gender, age, renal function, medical history and concomitant medication. Population parameters and interindividual variability were estimated using NONMEM® V software. Results Anti‐Xa activity was studied in 189 patients (mean age 82 ± 5 years, 22% weighing 1.0
ISSN:0306-5251
1365-2125
DOI:10.1111/j.1365-2125.2007.02920.x